Shares of Codexis Inc. (NASDAQ:CDXS) were up 3.6% during trading on Tuesday . The company traded as high as $4.34 and last traded at $4.34, with a volume of 56,355 shares changing hands. The stock had previously closed at $4.19.

A number of analysts have commented on CDXS shares. HC Wainwright started coverage on shares of Codexis in a research report on Wednesday, June 1st. They set a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, August 10th.

The company’s 50 day moving average price is $4.22 and its 200 day moving average price is $3.83. The stock’s market cap is $177.08 million.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings data on Tuesday, August 9th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.09. The company had revenue of $16 million for the quarter, compared to the consensus estimate of $15.10 million. The business’s revenue was up 166.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.14) earnings per share. Equities analysts expect that Codexis Inc. will post ($0.20) EPS for the current fiscal year.

In other news, major shareholder Vivo Ventures Vii, Llc sold 50,000 shares of Codexis stock in a transaction on Monday, August 15th. The shares were sold at an average price of $4.27, for a total transaction of $213,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 86,894 shares of Codexis stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $4.25, for a total transaction of $369,299.50. The disclosure for this sale can be found here.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.